Pericarditis Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE FOR MEDICAL MANAGEMENT (NSAID + Colchicine ± Biologic Therapy):

• Adults with a confirmed diagnosis of acute idiopathic or presumed viral pericarditis (pleuritic chest pain, pericardial friction rub, ECG changes, pericardial effusion on echocardiography — at least 2 of 4 diagnostic criteria per European Society of Cardiology 2015 guidelines)

• Patients with recurrent pericarditis (≥2 documented episodes) not controlled by standard NSAIDs alone

• Autoimmune pericarditis (SLE, rheumatoid arthritis, Sjögren syndrome) with positive ANA, anti-dsDNA, or anti-CCP antibodies

• Post-cardiac injury pericarditis (post-MI Dressler syndrome, post-pericardiotomy syndrome)

• Tuberculous pericarditis: eligible for adjunctive corticosteroid therapy alongside antituberculous chemotherapy

• Patients with refractory recurrent pericarditis unresponsive to colchicine who are candidates for IL-1 inhibitor therapy (anakinra or rilonacept)

• ELIGIBLE FOR PERICARDIOCENTESIS:

• Hemodynamically significant pericardial effusion causing cardiac tamponade (pulsus paradoxus >10 mmHg, hypotension, elevated JVP)

• Large pericardial effusion (>20 mm echo-free space) without clinical tamponade but with evidence of right-heart compromise

• Effusions requiring diagnostic sampling (suspected malignant, bacterial, or tuberculous etiology)

• Effusions unresponsive to medical therapy after 4 weeks

• ELIGIBLE FOR SURGICAL PERICARDIECTOMY:

• Chronic constrictive pericarditis with NYHA Class III–IV heart failure symptoms confirmed by:

· Transthoracic echocardiography (TTE): ventricular interdependence, septal bounce, dilated IVC, respiratory variation >25% in mitral inflow velocity

· Cardiac MRI: pericardial thickening >4 mm, late gadolinium enhancement indicating pericardial fibrosis, real-time cine imaging showing septal motion abnormalities

· CT thorax: pericardial calcification, thickening >4 mm (present in ~20–30% of constrictive cases)

· Right and left heart catheterization: diastolic pressure equalization, square-root sign, Kussmaul sign, LVEDP within 5 mmHg of RVEDP

• Persistent or recurrent large symptomatic effusions not manageable by repeat pericardiocentesis

• Purulent pericarditis requiring surgical drainage

• REQUIRED DIAGNOSTIC WORKUP:

• 12-lead ECG (diffuse ST elevation, PR depression, electrical alternans in tamponade)

• Transthoracic echocardiography (TTE) — essential for effusion quantification, tamponade physiology, constrictive assessment

• High-sensitivity C-reactive protein (hs-CRP), ESR, CBC with differential

• Troponin I or T (myopericarditis assessment; elevated in 30–35% of pericarditis cases)

• Antinuclear antibody (ANA), anti-dsDNA, complement levels (C3/C4), anti-CCP, RF (autoimmune screen)

• TSH, BUN, creatinine (uremic pericarditis exclusion)

• Blood cultures, tuberculin skin test or IGRA (QuantiFERON-TB Gold), adenosine deaminase if tuberculous etiology suspected

• Cardiac MRI with gadolinium: gold standard for detecting myocardial involvement, pericardial inflammation, fibrosis, and differentiating constrictive pericarditis from restrictive cardiomyopathy

• PET-CT with FDG: indicated in suspected malignant pericardial disease or systemic inflammatory conditions

• CT pulmonary angiography if pulmonary embolism is in the differential

• Pericardial fluid analysis (if drained): cell count, LDH, protein, glucose, culture, cytology, ADA, PCR for viruses and Mycobacterium tuberculosis

• CONTRAINDICATIONS / PRECAUTIONS:

• Aspirin/NSAID therapy contraindicated in patients on therapeutic anticoagulation (e.g., mechanical heart valves, active DVT/PE), severe renal impairment (eGFR <30), or active peptic ulcer disease — use gastroprotection (PPI) if NSAIDs essential

• Corticosteroids are a relative contraindication as first-line therapy for idiopathic pericarditis (increase recurrence risk) and are contraindicated in active untreated infection

• Pericardiectomy carries elevated operative mortality (5–12%) in patients with heavily calcified ('eggshell') pericardium, prior mediastinal irradiation, or severely reduced LV function (EF <30%) — must be weighed against symptom burden

• IL-1 inhibitor biologic therapy is contraindicated in active infection, immunocompromised states, or history of recurrent serious infection

TIER 1 — MEDICAL MANAGEMENT (First-Line for Acute and Recurrent Pericarditis):

NSAID + Colchicine Combination Therapy (COPE/ICAP Protocol): The backbone of acute pericarditis treatment is aspirin 750–1000 mg every 8 hours (2–4 weeks, tapered) or ibuprofen 600 mg every 8 hours (2–4 weeks, tapered), combined with colchicine 0.5 mg twice daily (body weight >70 kg) or 0.5 mg once daily (<70 kg) for a minimum of 3 months. The ICAP randomized controlled trial demonstrated that colchicine addition reduces 18-month recurrence from 32.3% to 16.7% (number needed to treat: 7). Therapy is guided by hs-CRP normalization — tapering begins only after hs-CRP reaches <1 mg/L, reducing the risk of symptom rebound.

Corticosteroid Therapy: Low-to-moderate dose prednisone (0.2–0.5 mg/kg/day, maximum 25 mg/day) is indicated for autoimmune pericarditis, uremic pericarditis, post-cardiac injury pericarditis, and cases where NSAIDs are contraindicated. High-dose corticosteroids are specifically avoided for idiopathic cases; the COPE trial showed they tripled the recurrence rate compared with aspirin. Mandatory concurrent colchicine co-administration during the steroid taper reduces rebound risk.

Antituberculous Therapy (ATT) + Adjunctive Steroids: Tuberculous pericarditis is treated with standard 4-drug ATT (isoniazid, rifampicin, pyrazinamide, ethambutol for 2 months, followed by 2-drug continuation for 4 months). The IMPI trial (2014) demonstrated that adjunctive prednisolone (1–2 mg/kg/day tapering over 6 weeks) significantly reduced constrictive pericarditis development and need for pericardiectomy in HIV-negative TB pericarditis patients.

TIER 2 — BIOLOGIC / ADVANCED MEDICAL THERAPY (Refractory Recurrent Pericarditis):

IL-1 Inhibition — Anakinra and Rilonacept: Anakinra (IL-1 receptor antagonist, 100 mg subcutaneous daily) has demonstrated efficacy in colchicine-resistant recurrent pericarditis in multiple observational studies and the AIRTRIP randomized trial (2016), achieving remission in >80% of refractory cases. Rilonacept (IL-1α/β trap, 320 mg subcutaneous loading dose followed by 160 mg weekly) received FDA approval in March 2021 based on the RHAPSODY trial, which demonstrated a 74.4% risk reduction in recurrence versus placebo, with a median time to recurrence in the placebo arm of 8.6 weeks. These biologics represent the most significant advance in pericarditis pharmacotherapy in two decades. Treatment is typically administered for 6–12 months with gradual weaning under hs-CRP monitoring.

Azathioprine and IVIG: Azathioprine (1–3 mg/kg/day) serves as a corticosteroid-sparing agent in autoimmune pericarditis and may be combined with low-dose prednisone during the tapering phase. Intravenous immunoglobulin (IVIG, 400–500 mg/kg/day for 5 days) is an established rescue therapy for corticosteroid-dependent recurrent pericarditis, especially in pediatric patients or those with significant steroid side effects.

TIER 3 — PROCEDURAL INTERVENTIONS:

Echo-Guided Pericardiocentesis: The preferred technique for hemodynamically significant pericardial effusion is real-time echocardiography-guided percutaneous pericardiocentesis via the subxiphoid or apical approach. A pigtail catheter is placed under echo and/or fluoroscopic guidance, allowing continuous drainage until output falls below 25–30 mL/24 hours (typically 24–72 hours). Success rates exceed 95% at experienced centers. Intrapericardial instillation of triamcinolone (600 mg/m²) at the time of drainage significantly reduces recurrence of idiopathic effusive pericarditis by up to 50% in published series.

Balloon Pericardiotomy / Pericardial Window: For recurrent symptomatic large effusions — particularly in malignant pericarditis — percutaneous balloon pericardiotomy creates a controlled pericardio-pleural communication allowing ongoing fluid drainage into the pleural space. Surgical pericardial window (subxiphoid or thoracoscopic) achieves the same goal with direct visualization; thoracoscopic window (VATS approach) offers the advantage of simultaneous tissue biopsy.

Surgical Pericardiectomy — Open and Video-Assisted: Pericardiectomy remains the definitive curative procedure for constrictive pericarditis. The two main surgical approaches are:

1. Median Sternotomy Pericardiectomy (Preferred for Extensive Constrictive Disease): Provides the widest operative field, allowing resection of the pericardium over both ventricles from phrenic nerve to phrenic nerve, including the posterior pericardium and pericardium over the great vessels. Cardiopulmonary bypass (CPB) is used selectively — approximately 25–30% of cases — when dense adhesions to the epicardium, heavy calcification ('eggshell pericardium'), or hemodynamic instability require it. Off-pump pericardiectomy, when feasible, avoids the coagulopathy and systemic inflammatory response associated with CPB. Operative mortality at high-volume centers is 5–8%; 5-year survival post-pericardiectomy is 80–83%. The Mayo Clinic risk scoring system (incorporating age, pre-op renal function, NYHA class, radiation etiology, and pre-op atrial fibrillation) predicts 30-day operative mortality.

2. Left Anterolateral Thoracotomy Pericardiectomy: An alternative for focal or less extensive pericardial constriction, particularly involving the left ventricular free wall. Offers excellent visualization of the left ventricle and avoids sternal division.

3. Video-Assisted Thoracoscopic (VATS) Pericardiectomy: Emerging minimally invasive approach for selected cases of focal constriction, recurrent effusions, or biopsy. Advantages include reduced hospital stay (3–5 days vs. 7–10 days for open), lower blood loss, and faster return to activity. Not yet suitable for extensive constrictive pericarditis with dense calcification or severe adhesions requiring CPB standby.

4. Robotic-Assisted Pericardiectomy: Available at select tertiary centers in India and the UAE, robotic assistance (da Vinci Surgical System) provides enhanced dexterity and 3D magnification for precise epicardial dissection in selected cases, minimizing the risk of cardiac laceration during adhesion release. Currently reserved for experienced robotic cardiac surgery programs.

Adjuvant Intraoperative Strategies: Intraoperative transesophageal echocardiography (TEE) guides the extent of pericardial resection and immediately identifies residual constriction or new wall motion abnormalities. Postoperative low-cardiac-output syndrome following pericardiectomy ('ventricular unclamping syndrome') is managed with phosphodiesterase inhibitors (milrinone), vasopressors, and occasionally intra-aortic balloon pump (IABP) support in the cardiac ICU.

PHASE 1 — PRE-ARRIVAL & TELECONSULTATION (2–4 weeks before travel):

• GAF Healthcare coordinator receives patient's medical records, ECG, echocardiography report, cardiac MRI or CT chest, laboratory results (hs-CRP, troponin, ANA panel, IGRA/TB screen), and current medication list

• Senior cardiologist or cardiothoracic surgeon at the partner hospital reviews records within 48–72 hours and issues a detailed treatment opinion with cost estimate

• GAF Healthcare assists with e-Medical Visa application (India) or UAE entry documentation; visa letters issued by the hospital within 3–5 working days

• Patient instructed to continue all current cardiac medications during travel; anticoagulation bridging protocol provided if relevant

• Patient advised to travel with a copy of recent ECG and echo report for emergency use during transit

PHASE 2 — ARRIVAL & DIAGNOSTIC CONFIRMATION (Days 1–3):

• Airport pickup by GAF Healthcare's dedicated medical transport team; wheelchair assistance arranged for NYHA Class III–IV patients

• Day 1: Admission to cardiology ward; repeat 12-lead ECG, hs-CRP, troponin, BMP/CMP, CBC, INR

• Day 1–2: Repeat transthoracic echocardiography (TTE) performed by cardiac imaging specialist to reassess effusion size, tamponade physiology, and constrictive features; transesophageal echocardiography (TEE) if TTE windows inadequate

• Day 2–3 (if surgical candidate): Cardiac MRI with late gadolinium enhancement to quantify pericardial inflammation and fibrosis; right and left heart catheterization for hemodynamic confirmation of constrictive physiology; pulmonary function tests (pre-operative baseline for pericardiectomy candidates); anesthesiology pre-assessment

• Day 2 (if urgent effusion/tamponade): Emergency pericardiocentesis performed in cardiac catheterization laboratory or echocardiography suite under real-time echo guidance; immediate hemodynamic relief expected

• Multidisciplinary team review (cardiologist, cardiothoracic surgeon, cardiac imaging specialist, anesthesiologist, rheumatologist if autoimmune etiology) to finalize treatment plan

PHASE 3A — MEDICAL MANAGEMENT PATHWAY (Days 3–7, for acute/recurrent pericarditis without surgical indication):

• Initiation of NSAID + colchicine protocol with therapeutic drug monitoring; gastroprotection with proton pump inhibitor co-prescribed

• Daily hs-CRP measurement to track anti-inflammatory response

• Cardiac monitoring on telemetry for 24–48 hours to detect rhythm disturbances (atrial fibrillation occurs in 5–10% of acute pericarditis)

• For autoimmune cases: initiation of low-dose prednisone taper with documented hs-CRP normalization as taper criterion

• For refractory cases: subcutaneous anakinra initiated in-hospital with first dose under nursing supervision; patient and attendant trained in self-injection technique

• Day 5–7: Repeat hs-CRP and echocardiography; if effusion resolved/stable and hs-CRP trending down, discharge planning initiated

• Hospital discharge with detailed written medication schedule (colchicine duration: 3 months minimum), hs-CRP monitoring schedule, and digital follow-up plan via GAF Healthcare teleconsultation platform

PHASE 3B — SURGICAL PATHWAY (for pericardiocentesis or pericardiectomy):

• Pericardiocentesis (if required): Performed Day 1–3 under echocardiographic guidance; pigtail catheter left in situ for 24–72 hours; output monitored every 4–6 hours; catheter removed when output <25 mL/24 hours; 2-hour post-procedure echo confirms pericardial decompression; patient discharged after 24-hour observation

• Pericardiectomy (elective, constrictive pericarditis):

· Day 3 (Pre-operative): Cardiac surgery consent; blood group and cross-match; skin preparation; nil by mouth from midnight

· Day 4 (Operative day): Transfer to cardiac surgical suite; general anesthesia with intraoperative TEE probe placed; median sternotomy or left anterolateral thoracotomy performed; systematic pericardiectomy from phrenic nerve to phrenic nerve with meticulous epicardial dissection; CPB on standby (used selectively ~25–30%); average operative time 2.5–4 hours; patient transferred to cardiac ICU intubated

· Days 4–6 (Cardiac ICU): Mechanical ventilation weaned within 6–12 hours of uncomplicated surgery; vasopressors and milrinone titrated for low-output syndrome management; chest drains monitored; continuous cardiac monitoring; daily echo assessment of ventricular function recovery

· Days 6–10 (Step-down ward): Chest drains removed when output <150 mL/24 hours; progressive mobilization with cardiac physiotherapy; oral analgesics; sternal wound care; patient education on sternal precautions (6–8 weeks)

· Day 10: Pre-discharge transthoracic echocardiography; hs-CRP level; chest X-ray; wound inspection

· Discharge with written sternal precautions, medication reconciliation (continued colchicine 3 months post-surgery reduces post-pericardiectomy syndrome risk), and GAF Healthcare follow-up teleconsultation schedule

PHASE 4 — POST-DISCHARGE RECOVERY & FIT-TO-FLY:

• Medical management pathway: Recommend minimum 7–10 days post-discharge in-country observation; repeat echo and hs-CRP at Day 7 post-discharge; if stable, cleared for international travel at Week 2 post-discharge

• Pericardiectomy pathway: Minimum 3–4 weeks post-operative in-country stay before intercontinental flight; cleared for flight only after cardiac surgeon confirmation of sternal stability, absence of pleural effusion, and hs-CRP normalization

• GAF Healthcare arranges serviced apartment accommodation near the hospital for attendant and recuperating patient during post-discharge observation period

• All discharge documents, imaging discs, operative notes, histopathology reports, and a personalized cardiologist letter translated into the patient's home country language

• Week 4 and Month 3 virtual follow-up consultations via GAF Healthcare's secure telemedicine platform; hs-CRP results from patient's local laboratory reviewed remotely